Options
Immunosenescence profile and expression of the aging biomarker (p16INK4a) in testicular cancer survivors treated with chemotherapy
Journal
BMC Cancer
ISSN
1471-2407
Date Issued
2020
Author(s)
Velazquez, Hugo E.
Hinojosa, Juan
Orozco, Luis
Rios-Corzo, Ricardo
Lima, Guadalupe
Llorente, Luis
Hernandez-Ramirez, Diego F.
Valentin-Cortez, Francisco J.
Medina-Rangel, Irene
Atisha-Fregoso, Yemil
Type
Resource Types::text::journal::journal article
Abstract
Background: Cytotoxic chemotherapy can cure advanced germ cell tumors. Nevertheless, cancer treatment may induce cellular senescence and accelerate molecular aging. The aging process implies an increase of cells expressing p16INK4a and changes in lymphocyte subpopulations. Our aim was to study the potential induction of premature immunosenescence in testicular cancer survivors (TCS) exposed to chemotherapy. Methods: Case-control exploratory study of TCS treated with chemotherapy (≥3 BEP cycles, disease-free ≥3 months) compared with age matched healthy controls. Peripheral blood mononuclear cells were isolated, and lymphocyte subpopulations were analyzed by flow cytometry. CDKN2A/p16INK4a expression in T cells was measured using qPCR. The percentage of lymphocyte subpopulations and the CDKN2A/p16INK4a expression in TCS were compared with the control group using the Wilcoxon signed-rank test.